Pertuzumab combined with trastuzumab compared to trastuzumab in the treatment of HER2-positive breast cancer: A systematic review and meta-analysis of randomized controlled trials

Overview of attention for article published in Frontiers in oncology, September 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 33 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 3 X users, with an upper bound of 30,880 followers.

RT @DrImranSheikh: Pertuzumab combined with trastuzumab compared to trastuzumab in the treatment of HER2-positive breast cancer: A systemat…

29 Sep 2022

Reply Repost Favourite

Pertuzumab combined with trastuzumab compared to trastuzumab in the treatment of HER2-positive breast cancer: A systematic review and meta-analysis of randomized controlled trials: Objective, Although dual anti-HER2 therapy, #oncology… https://t.co/eDzLqe

29 Sep 2022

Reply Repost Favourite

RT @FrontOncology: New research: Pertuzumab combined with trastuzumab compared to trastuzumab in the treatment of HER2-positive breast canc…

29 Sep 2022

Reply Repost Favourite

New research: Pertuzumab combined with trastuzumab compared to trastuzumab in the treatment of HER2-positive breast cancer: A systematic review and meta-analysis of randomized controlled trials: Objective Although dual anti-HER2 therapy,… https://t.co/lJ1

29 Sep 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.